Boston-based researchers and Johnson & Johnson have joined forces in a five-year, $30 million deal to produce fast and cheap tests to detect even tiny amounts of cancer cells in the bloodstream. The groundbreaking new technology would make treatments more effective, as monitoring cancer levels becomes quicker and easier, and would allow doctors to test specific DNA in cancer cells, seen as essential to treating the disease. Of the current technology, one scientist said, “We’re limited by our ability to make it fast, easy, cheap, and something that could be done on a global scale.”
Read it at The Boston Globe
